A “deluge” of opportunities presented themselves to Merck Serono after the Switzerland-based biotechnology company lifted the lid on its corporate venturing fund last year and provided almost immediate justification for the decision to start a €40m ($49m) in-house venture capital operation. Receiving more than 400 business plans in the first nine months, however, caused some…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
